Clinical trials for cancer patients
The Clínica is the private center that promotes the most clinical trials in Spain. We aim to generate knowledge to change the course of diseases.
-
December 5, 2024PamplonaIn recruitmentEarly phase
MCLA-158-CL01 MCLA-158 trial in metastatic colorectal cancer and other advanced solid tumors.
This clinical study will evaluate the safety of MCLA-158 in patients with metastatic colorectal cancer and other advanced solid tumors. -
December 5, 2024Pamplona/MadridIn recruitment
M24-287 [SP]
The primary objective is to assess the incidence of treatment-emergent laboratory TLS according to Howard's criteria (Appendix D) or hyperkalemia (potassium > 6.0 mmol/L) requiring clinical intervention as assessed by the Independent Review Committee (IRC) in previously untreated CLL subjects who have reached a median level (any lymph node). (CRI) in previously untreated CLL patients with a median extent (any lymph node [LN] of 5 cm). lymph nodes [LN] from 5 cm to < 10 cm OR absolute l... -
December 5, 2024MadridIn recruitmentEarly phase
MS201924_0002 Tuvusertib combinado con niraparib o lartesertib en participantes con cáncer epitelial de ovario. [SP]
El principal obejtivo es analizar sus muestras, junto con su información personal y las imágenes obtenidas como parte del ensayo principal para estudiar los genes, averiguar cómo se relacionan estos genes y las variaciones genéticas con la manera en que actúa el tratamiento del ensayo o saber más sobre su enfermedad y la respuesta al tratamiento. -
November 27, 2024Pamplona/MadridIn recruitment
20200041 Trial of tarlatamab in combination with durvalumab vs. durvalumab monotherapy in subjects with extended stage small cell lung cancer after platinum, etoposide and durvalumab.
This study is being conducted to learn more about treatment with tarlatamab and durvalumab or durvalumab alone in people with extended-stage small cell lung cancer (ESSCLC), a disease in which cancer cells form in the tissues of the lung and spread to other parts of the body such as the other lung, bones, brain or bone marrow. -
November 27, 2024Pamplona/MadridIn recruitment
D9970C00001 Phase I/IIa clinical trial of AZD3470 in monotherapy and in combination with anticancer agents in patients with advanced or metastatic MTAP-deficient solid tumors.
The objective of the trial is to evaluate the safety and tolerability and determine the RP2D of AZD3470 as monotherapy and in combination with anticancer agents in participants with MTAP advanced solid tumors. -
November 26, 2024Pamplona/MadridIn recruitment
-
November 25, 2024PamplonaIn recruitment
EGL-121 Clinical trial of EGL-001 in adult patients with certain advanced and/or metastatic solid tumors
The primary objective of this study is to assess the safety and tolerability of EGL-001 in participants with certain advanced and/or metastatic solid tumors that have shown progression after previously benefiting from standard treatment with an immune checkpoint inhibitor -
November 25, 2024Pamplona/MadridIn recruitment
DB-1303-O-3002 Phase III, randomized, multicenter, open-label study to evaluate DB-1303 versus investigator's choice of chemotherapy in patients with metastatic breast cancer
The primary objective is to evaluate the efficacy of DB-1303 compared to investigator's choice of chemotherapy in terms of a hazard ratio (HR) for progression-free survival (PFS) assessed by blinded independent central review (BICR) in the HR+, HER2-low population (IHC 2+ and IHC 1+). The intercurrent event of initiating subsequent anticancer therapy will follow a hypothetical strategy, and study treatment discontinuation will follow a treatment policy strategy. -
November 24, 2024Pamplona/MadridIn recruitment
20230016 Clinical trial on treatment with tarlatamab in subjects with limited-stage small cell lung cancer (LS-SCLC) who have not progressed following concurrent chemoradiotherapy (DeLLphi-306)
The objective of this study is to gather more information about tarlatamab (AMG 757) compared to placebo in individuals with limited-stage small cell lung cancer (LS-SCLC). The purpose of this study is to evaluate the drug's efficacy and whether it causes any side effects. -
November 18, 2024MadridIn recruitmentEarly phase
BOT-112-204 Phase 2b clinical trial to evaluate the safety of intralesional BO-112 in patients with primary resectable low-risk and high-risk basal cell carcinoma.
The main objective is to evaluate the efficacy of BO-112. administered by IL injection in patients with primary resectable low-risk or high-risk BCC, respectively.